CD19-targeting FDA-approved immunotherapies for BCP-ALL include blinatumomab and tisagenlecleucel; CD22 and dual targeting (CD19/CD22) CAR T-cell therapies are under investigation and available through clinical trials (14–16). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.